- Recent news combined an FDA warning letter to Walmart over unapproved STI drug products sold via Walmart.com with the retailer’s plan to cover more than 250 prescription medicines at no cost for US associates starting in 2027, alongside expanded specialist care programs and NICU leave.
- The pairing of tighter regulatory scrutiny on Walmart’s online health related offerings with richer in house medical benefits highlights rising compliance and benefit costs that sit directly against the firm’s long term push to use healthcare and pharmacy services as a competitive edge.
- The next area of focus will be how Walmart’s investment narrative incorporates richer employee drug coverage while managing higher regulatory risk around online health products.
Scan beyond Walmart and explore this FDA spotlight on healthcare and e-commerce oversight by reviewing a curated group of retailers and pharmacies with solid fundamentals in our list of solid balance sheet and fundamentals (25 results)
Walmart Investment Narrative Recap
To own Walmart, you need to believe its omnichannel model and higher margin businesses like Walmart Connect, marketplace fees and memberships can keep doing more of the heavy lifting while heavy capex and automation costs are brought under control. The short term catalyst is execution on profitable e commerce growth after ten quarters of at least 20% expansion and six profitable quarters.
The FDA warning letter adds to an already clear risk around regulatory scrutiny of Walmart’s digital tools and online assortment. It looks incremental rather than thesis breaking but could modestly raise compliance costs and slow parts of marketplace growth if assortment tightening is required.
The most relevant counterweight to the FDA action is Walmart’s plan to cover more than 250 prescription medicines at no cost for US associates starting in 2027, alongside expanded specialist care and NICU leave. That move pushes deeper into healthcare, an area already under closer regulatory review after questions about AI, digital pricing tools and now STI related products online.
For you as an investor, this set of announcements ties Walmart’s biggest near term opportunity and risk to the same arena. Healthcare and pharmacy services, membership, advertising and marketplace can support margins and engagement, but tighter oversight of how products are marketed and priced digitally could trim some of that upside through higher ongoing compliance effort.
Walmart's current analyst narrative points to revenues of $839.4b and earnings of $29.5b by 2029, based on 4.5% yearly revenue growth and an earnings increase of about $7.4b from $22.1b today.
Uncover why Walmart's fair value indicates a 13% potential upside to its current price that may not last much longer.
Exploring Other Perspectives
Across 13 fair value estimates from the Simply Wall St Community, opinions on Walmart stretch from about $65.80 to $154.58 per share, a very wide span that highlights both deep pessimism and strong optimism. This should be considered alongside rising automation capex, tighter FDA oversight and higher healthcare benefits. You should expect sharply different views and explore several alternatives before deciding where you stand.
Explore 12 other Walmart fair value estimates, including one that suggests as much as 41% downside from the current price!
Form Your Own Verdict
Don't just follow the ticker. Dig into the data and build a conviction that's truly your own.
- A great starting point for your Walmart research is our analysis highlighting 2 key rewards that could impact your investment decision.
- See our latest analysis for Walmart. The report includes a comprehensive fundamental analysis summarized in a single visual, the Snowflake, making it easy to evaluate Walmart's overall financial health at a glance.
Looking for more Walmart sized investment ideas?
If this Walmart review has sharpened your thinking, use the Simply Wall St Screener to line up other companies that fit the kind of profile you want to research next.
- If you want companies that already screen well on balance sheet strength and fundamentals, start with this curated list of solid balance sheet and fundamentals (25 results) and look for businesses that match your risk tolerance.
- For investors hunting for mispriced quality, scan our hand picked 32 high quality undervalued stocks and see which stocks merit a spot on your watchlist.
- If your focus leans toward resilience over excitement, review the 32 resilient stocks with low risk scores and build a shortlist of candidates to research in more depth.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com